Brokerages Set Pacira BioSciences, Inc. (NASDAQ:PCRX) PT at $26.44

Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Get Free Report) have received a consensus recommendation of "Hold" from the nine ratings firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $26.44.

Several research firms have weighed in on PCRX. Wall Street Zen raised shares of Pacira BioSciences from a "hold" rating to a "buy" rating in a research note on Friday, June 6th. HC Wainwright boosted their price objective on shares of Pacira BioSciences from $48.00 to $65.00 and gave the company a "buy" rating in a research report on Tuesday, April 8th. Finally, Needham & Company LLC decreased their price objective on shares of Pacira BioSciences from $32.00 to $30.00 and set a "buy" rating on the stock in a research report on Friday, May 9th.

Insider Activity

In related news, SVP Lauren Riker sold 5,578 shares of the business's stock in a transaction dated Wednesday, June 4th. The shares were sold at an average price of $26.21, for a total transaction of $146,199.38. Following the transaction, the senior vice president owned 59,564 shares in the company, valued at $1,561,172.44. The trade was a 8.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 6.40% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Pacira BioSciences

Several hedge funds and other institutional investors have recently modified their holdings of PCRX. Allspring Global Investments Holdings LLC bought a new stake in Pacira BioSciences during the first quarter worth about $277,000. ProShare Advisors LLC boosted its stake in Pacira BioSciences by 30.2% during the fourth quarter. ProShare Advisors LLC now owns 16,003 shares of the company's stock worth $301,000 after acquiring an additional 3,710 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Pacira BioSciences by 16.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 502,204 shares of the company's stock worth $9,462,000 after acquiring an additional 70,307 shares in the last quarter. GAMMA Investing LLC boosted its stake in Pacira BioSciences by 112.8% during the first quarter. GAMMA Investing LLC now owns 3,694 shares of the company's stock worth $92,000 after acquiring an additional 1,958 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Pacira BioSciences by 3.1% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,077 shares of the company's stock worth $491,000 after acquiring an additional 794 shares in the last quarter. Hedge funds and other institutional investors own 99.73% of the company's stock.

Pacira BioSciences Price Performance

NASDAQ:PCRX traded down $0.13 during trading hours on Friday, hitting $22.60. The stock had a trading volume of 401,846 shares, compared to its average volume of 894,889. The company has a 50 day simple moving average of $24.71 and a two-hundred day simple moving average of $24.33. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.41 and a quick ratio of 1.99. Pacira BioSciences has a one year low of $11.16 and a one year high of $27.64. The firm has a market capitalization of $1.05 billion, a price-to-earnings ratio of -9.91 and a beta of 0.48.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.